<DOC>
	<DOCNO>NCT00079638</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness first-line treatment use Niaspan ( extended release version niacin ) statins versus drug lower lipid level , subject elevate fat level blood ( dyslipidemia ) . Statins class medication often prescribed patient need low cholesterol level .</brief_summary>
	<brief_title>Comparative Efficacy Evaluation Lipids When Treated With Niaspan &amp; Statin Other Lipid-Modifying Therapies-COMPELL</brief_title>
	<detailed_description>Name Drugs : Niaspan ( niacin extended-release tablet ) , Lipitor® ( atorvastatin ) , Zocor® ( simvastatin ) , Zetia™ ( ezetimibe ) , Crestor® ( rosuvastatin ) Study Treatment : Four open-label parallel treatment group 12 week observation - Niaspan atorvastatin combination treatment titrated 2000 mg 40 mg , respectively ; - combination treatment simvastatin titrate 40 mg ezetimibe maintain 10 mg ; - rosuvastatin monotherapy treatment titrate 40 mg ; - Niaspan rosuvastatin combination treatment titrated 1000 mg 20 mg , respectively . Objective : To evaluate relative efficacy first-line therapy use combination Niaspan atorvastatin versus combination simvastatin ezetimibe versus rosuvastatin monotherapy versus combination Niaspan rosuvastatin patient dyslipidemia . Population : - Male female patient 21 year age old - Patients eligible treatment base upon National Cholesterol Education Program Adult Treatment Panel III ( NCEP-ATP III ) recommendation end Qualification period ; - All patient must mean triglyceride ( TG ) ≤ 300 mg/dL . Design : A Phase IV , 12-week , randomize , multi-center , open-label , four-arm , parallel-group study evaluate efficacy Niaspan statin therapy versus lipid-modifying therapy precede four-week washout previous lipid-lowering therapy .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>All following criterion must answer “ Yes ” : 1 . Patient 21 year age old willing participate duration study ; 2 . Patient read , sign , agree item list informed consent form HIPAA authorization form prior initiation study procedure and/or discontinue medication ; 3 . Patient eligible treatment follow drug washout period base upon NCEP ATP III entry criterion LDLC variability ≤ 15 % ; 4 . Patient mean triglyceride level ( TG ) ≤ 300 mg/dL ; 5 . Patient willing withdraw current antidyslipidemic medication prohibit medication approximately 6 week prior randomization ( 4 week prior qualification visit ) duration study ; 6 . If patient female , patient must pregnant breastfeed plan become pregnant breastfeed duration study . Women childbearing potential must commit use medically acceptable method birth control oral contraception , intrauterine device ( IUD ) , doublebarrier method contraception . Women use oral contraception must do least 3 month prior randomization , continue duration study . To consider childbearing potential , woman must postmenopausal least 2 year surgically sterile . All following criterion must answer “ No ” : 1 . Patient allergy , hypersensitivity , intolerance niacin , simvastatin , atorvastatin , ezetimibe , rosuvastatin derivative ; 2 . Patient drink 14 alcoholic drink per week previous history ( within 12 month screen ) substance abuse dependency ; 3 . Patient untreated unsuccessfully treat psychiatric disease ; 4 . Patient use investigational study medication participate investigational study within 30 day obtain qualification lab ; 5 . Patient take prohibited medication within 4 week obtain qualification lab study ( See section 8.0 Concomitant Medications ) ; 6 . Patient history follow : active gallbladder disease within precede 12 month ( cholecystectomy allow ) ; pancreatitis ; liver disease ( e.g. , hepatitis B and/or C ) ; persistent uncontrolled untreated severe hypertension ; Type I Type II diabetes ; persistent uncontrolled untreated hypothyroidism ; arterial bleeding ; unstable angina ; myocardial infarction , coronary artery bypass graft surgery , angioplasty within precede 6 month ; stroke , transient ischemic attack ( TIA ) , deep vein thrombosis ( DVT ) within precede 6 month ; congestive heart failure NYHA class III IV ; active cancer within last 5 year diagnosis cancer within last 5 year ( exclude basal cell carcinoma ) ; fibromyalgia , myopathy , rhabdomyolysis , unexplained muscle pain weakness , and/or discontinuation statin myalgia ; and/or life expectancy &lt; 2 year . 7 . Patient follow abnormality Screening Qualification Visits : CPK elevation &gt; 3xULN ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 1.3xULN ; serum creatinine ≥ 1.5 mg/dL ; creatinine clearance &lt; 30 mL/min , calculate use Cockroft Gault formula central laboratory ; active gout symptom and/or uric acid level &gt; 1.3xULN ; and/or active peptic ulcer disease ; 8 . Patient plan undergo major surgery within next 6 month ; 9 . Patient health condition laboratory abnormality , opinion Principal Investigator , may adversely affected procedure medication study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Niaspan</keyword>
	<keyword>Niacin</keyword>
	<keyword>Statin</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>Lipid-Modifying Therapies</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Coronary Heart Disease</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Stroke</keyword>
	<keyword>VA-HIT</keyword>
	<keyword>Niacin Statin Combination Threrapy</keyword>
	<keyword>High Density Lipoprotein</keyword>
	<keyword>Low Density Lipoprotein</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Adult Treatment Panel III</keyword>
</DOC>